



OMS *life* Foundation

OMS Patient Registry & Natural History Study

OMS Workshop – Abingdon, England

October 6, 2022

A recap of some questions from 2014 workshop*

Plan of action for quicker diagnosis

- Most patients **DO NOT** see an OMS specialist
- Median time to diagnose in 2014 was > 30 days

- Contributing factors include collaborative efforts, publications, Board Exams, social media, websites, and caregivers' persistence

Consensus on treatment & Treating physician playbook

- A consensus on treatment
- Consensus statement testimonies
 - Treatments changed
 - Specialists consulted
- Collaboration among medical professionals

* From January 2014 OMS Workshop



A recap of some questions from 2014 workshop*

Caregiver playbook

- NORD information
- NORD collaboration video
- [Back to School documents](#)
- Consensus statement
- Insurance – insurance letter
- OMS Caregiver Conferences (7 to date)
- [Publication Repository](#)
 - OMS Box Notes - [OMS Publications & Research | Powered by Box](#)
 - Bhavna Diaz

Plan of action for Latin America & Guide on Adult OMS

* From January 2014 OMS Workshop



OMSLife Registry

History

- Grant received from NORD via FDA in 2016
 - One of 10 rare diseases to receive the grant
- Patient self-report registry involving fifteen unique surveys, with 370 patients enrolled
- Self-report data provides valuable **complement** to clinically-obtained metrics

Overview & Registry Aims

- Parents able to provide rich, detailed insight into their child's OMS characteristics, course of care, and day-to-day life
- **Doctors are able to see trends over time and beyond disease onset**



OMSLife Registry

Potential


- Find patients outside of the “specialists” areas
- Large untapped group of patients remains
- Able to ramp up surveys for specific questions

Boston Children’s Collaboration, Data Analysis & Publication

- Ongoing collaboration between OMSLife and Boston Children’s Hospital
- Primary areas of interest: demographics, treatment, and time-to-diagnosis
- Goal will be to examine ongoing disease characteristics, treatment trends over time
- Initial manuscript submission expected fall 2022



The OMS patient network has grown over 12 years*



* Sources includes social media, OMS caregiver conferences, doctor referrals, web: NORD, Dr. P's MCDonald House, OMSLife register, family referrals, etc...



OMSLife Registry Studies

Trio Health, NORD, OMSLife Collaboration 2019

- General demographic data previously published
- Shows that the data can be trusted
- Data updated annually
- Capturing patients from many years

Boston Children's Hospital Collaboration 2022


- General demographic data from 2020 data set of patients
- Plans are being developed for continued collaborative efforts on trends of OMS patients over time
- Opportunities to grow the BCH registry with new patients out side the participating group of hospitals




3. PATIENT DEMOGRAPHICS

As of Sep 2018, 275 patients or caregivers registered and 196 contributed data to the registry; 74 patients filled out all available surveys.


Gender (n=170)




Race (n=196)



Country of Residence (n=169)




Age at Diagnosis (n=166)



Age (months)	Overall	Pediatric
min	2.0	2.0
25th percentile	12.0	12.0
median	20.0	19.5
mean	33.3	22.5
75th percentile	24.0	24.0
max	420.0	120.0
n	166	160

4. PATIENT DEMOGRAPHICS


Insurance Type (n=159)



Family Income Level (n=137)




Highest Education Level in Household (n=164)



4. ASSOCIATIONS OF SYMPTOMS AT ONSET


Frequency of other symptoms at onset for each individual symptom. Arrows in higher or lower likelihood than expected from the population distribution base standardized residuals.

■ Not Significant ■ Significant (p<0.05)




3. SYMPTOMS AT ONSET

Ataxia (87%, 131/150) was the most common symptom at onset.




5. TIME TO DIAGNOSIS AND DIAGNOSING PROVIDER

Most (69%) patients were diagnosed by 3 months following onset of symptoms.



6. DISEASE SEVERITY


The Mitchell-Pike OMS Severity Scale classifies OMS cases as mild (0-6), moderate (7-12), or severe (13-18). The aggregate score is based on 6 individual assessments, with a score of 0 (normal) to 3 (severe impairment or state) assigned individually for stance, gait, arm/hand function, opsoclonus, mood/behavior, and speech.




3. TYPES OF THERAPIES

Of the 117 respondents, 83% received more than 1 type of therapy.

% of Patients by # of Therapy Types Received




% of Patients receiving each Therapy Type




4. ASSOCIATION OF THERAPY TYPES

Past or present use of other therapy types for patients with specified type of therapy

- Most respondents received occupational, physical, or speech therapy
- Multiple therapeutic approaches were common




- Frequency or sessions per week varied by therapy type
- Physical therapy had the greatest fraction of patients receiving >1 session per week (56%)



Respondent perception of therapy

- ≥90% of respondents indicated that specified therapy was beneficial



And new opportunities for the 2022 workshop

Behavioral issues

- Can the registry help gather behavioral data?
- Are Sensory Processing Disorders (SPD) being misdiagnosed as behavioral issues?
- Are there Occupational Therapy solutions?

Plan of action for Latin America & Guide on Adult OMS

- Collaboration with Latin American doctors
- Development of Spanish publications
- Adult onset of OMS
- Transition of pediatric patients to adult care



The OMSLife Foundation

P.O. BOX 2899

Cypress, TX 77410

432-638-9194

Mike@OMSLifefoundation.org

www.omslifefoundation.org



Find us at OMSLife
or OMSLifeInformation

